Author | Mannie, Mark D. | |
Author | Curtis II, Alan Dale | |
Date Accessioned | 2020-04-02T19:16:53Z | |
Date Available | 2020-04-02T19:16:53Z | |
Date of Issue | 2013-01-28 | |
Identifier (URI) | http://hdl.handle.net/10342/7818 | |
Description | Tolerogenic vaccines represent a new class of vaccine designed to re-establish immunological tolerance, restore immune homeostasis, and thereby reverse autoimmune disease. Tolerogenic vaccines induce long-term, antigen-specific, inhibitory memory that blocks pathogenic T cell responses via loss of effector T cells and gain of regulatory T cell function. Substantial advances have been realized in the generation of tolerogenic vaccines that inhibit experimental autoimmune encephalomyelitis in a preclinical setting, and these vaccines may be a prequel of the tolerogenic vaccines that may have therapeutic benefit in Multiple Sclerosis. The purpose here is to provide a snapshot of the current concepts and future prospects of tolerogenic vaccination for Multiple Sclerosis, along with the central challenges to clinical application. | en_US |
Subject | autoimmune disease, experimental autoimmune encephalomyelitis, immune, multiple sclerosis, myelin, neuroantigen, T lymphocytes, therapy, tolerance, vaccine | en_US |
Title | Tolerogenic vaccines for multiple sclerosis | en_US |
Type | Article | en_US |
Identifier (DOI) | 10.4161/hv.23685 | |
Journal Name | Hum Vaccin Immunother | en_US |
Journal Volume | 9 | en_US |
Journal Issue | 5 | en_US |
Article Pages | 1032–1038 | en_US |